Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 3, 2013, Pages 317-323

  Scott, S A ^a   Sangkuhl, K ^b   Stein, C M ^c   Hulot, J S ^a,d   Mega, J L ^e   Roden, D M ^c   Klein, T E ^b   Sabatine, M S ^e   Johnson, J A ^f,g,h   Shuldiner, A R ^i,j  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SORBONNE UNIVERSITÉ   (France)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f Department of Pharmacotherapy and Translational Research   (United States)

^g UNIVERSITY OF FLORIDA   (United States)

^h UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

ⁱ UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^j BALTIMORE VA MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

ACUTE CORONARY SYNDROME; ALLELE; ARTICLE; DRUG DOSE ESCALATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; LOSS OF FUNCTION MUTATION; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; GENETICS; RISK ASSESSMENT;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2C19; GENETIC TESTING; GENETIC VARIATION; GENOTYPE; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; TICLOPIDINE;

EID: 84883170442     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.105     Document Type: Article

References (40)

1. Scott, S.A. et al.; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin. Pharmacol. Ther. 90, 328-332 (2011).
2. Relling, M.V. & Klein, T.E. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 89, 464-467 (2011).
3. Bouman, H.J. et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat. Med. 17, 110-116 (2011).
4. Reny, J.L., Combescure, C., Daali, Y. & Fontana, P.; PON1 Meta-Analysis Group. Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis. J. Thromb. Haemost. 10, 1242-1251 (2012).
5. Scott, S.A. et al. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet. Genomics 22, 159-165 (2012).
6. Hulot, J.S. et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108, 2244-2247 (2006).
7. Brandt, J.T. et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost. 5, 2429-2436 (2007).
8. Giusti, B. et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet. Genomics 17, 1057-1064 (2007).
9. Collet, J.P. et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373, 309-317 (2009).
10. Mega, J.L. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354-362 (2009).
11. Shuldiner, A.R. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302, 849-857 (2009).
12. Frére, C., Cuisset, T., Gaborit, B., Alessi, M.C. & Hulot, J.S. The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. J. Thromb. Haemost. 7, 1409-1411 (2009).
13. Sibbing, D. et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J. Thromb. Haemost. 8, 1685-1693 (2010).
14. Tiroch, K.A. et al. Protective effect of the CYP2C19*17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am. Heart J. 160, 506-512 (2010).
15. Sibbing, D. et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121, 512-518 (2010).
16. Li, Y., Tang, H.L., Hu, Y.F. & Xie, H.G. The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. J. Thromb. Haemost. 10, 199-206 (2012).
17. Geisler, T. et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 9, 1251-1259 (2008).
18. Simon, T. et al.; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363-375 (2009).
19. Sorich, M.J., Polasek, T.M. & Wiese, M.D. Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding. Thromb. Haemost. 108, 199-200 (2012).
20. Lewis, J. et al. The CYP2C19*17 variant is not independently associated with clopidogrel response. J. Thromb. Haemost. (2013); e-pub ahead of print 29 June 2013.
21. Hulot, J.S. et al. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in postmyocardial infarction patients. Circ. Cardiovasc. Interv. 4, 422-428 (2011).
22. Giusti, B. et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am. J. Cardiol. 103, 806-811 (2009).
23. Sibbing, D. et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur. Heart J. 30, 916-922 (2009).
24. Cayla, G. et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA 306, 1765-1774 (2011).
25. Paré, G. et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N. Engl. J. Med. 363, 1704-1714 (2010).
26. Holmes, M.V., Perel, P., Shah, T., Hingorani, A.D. & Casas, J.P. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 306, 2704-2714 (2011).
27. Mega, J.L. et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304, 1821-1830 (2010).
28. Johnson, J.A., Roden, D.M., Lesko, L.J., Ashley, E., Klein, T.E. & Shuldiner, A.R. Clopidogrel: a case for indication-specific pharmacogenetics. Clin. Pharmacol. Ther. 91, 774-776 (2012).
29. Jneid, H. et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 60, 645-681 (2012).
30. Wiviott, S.D. et al.; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007).
31. Mega, J.L. et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119, 2553-2560 (2009).
32. Sorich, M.J., Vitry, A., Ward, M.B., Horowitz, J.D. & McKinnon, R.A. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J. Thromb. Haemost. 8, 1678-1684 (2010).
33. Wallentin, L. et al.; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045-1057 (2009).
34. Hulot, J.S., Collet, J.P. & Montalescot, G. Genetic substudy of the PLATO trial. Lancet 377, 637, author reply 637-637, author reply 638 (2011).
35. Wallentin, L. et al. Prasugrel achieves greater and faster P2Y12receptormediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur. Heart J. 29, 21-30 (2008).
36. Pena, A. et al. Can we override clopidogrel resistance? Circulation 119, 2854-2857 (2009).
37. Montalescot, G. et al. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb. Haemost. 103, 213-223 (2010).
38. Price, M.J. et al.; GRAVITAS Investigators. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305, 1097-1105 (2011).
39. Collet, J.P. et al.; ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N. Engl. J. Med. 367, 2100-2109 (2012).
40. Wallentin, L. et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376, 1320-1328 (2010).